In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia

The in vivo efficacies of levofloxacin and ciprofloxacin in lethal, systemic Pseudomonas aeruginosa infections in mice were compared. MICs of levofloxacin and ciprofloxacin ranged from 0.5 to 2.0 micrograms/ml and from 0.12 to 1.0 microgram/ml respectively. Infecting doses ranged from 5.0 x 10(1) to 3.2 x 10(3) CFU per mouse, depending on the isolate. Test fluoroquinolones were administered orally at 1 h (single dose) or at 1 and 3 h (divided dose) postinfection, with 10 infected mice used for each of six concentrations of each fluoroquinolone tested (1 to 40 mg/kg of body weight) in each dosing regimen. Whether given in a single or a divided dose, the total daily dose was the same for each fluoroquinolone. For mice treated 1 h postinfection with levofloxacin and ciprofloxacin, the effective doses for 50% of the infected mice ranged from 2.09 to 13.80 mg/kg and from 2.34 to 11.22 mg/kg, respectively, and for those treated 1 and 3 h postinfection, the effective doses for 50% of the infected mice ranged from 3.71 to 16.98 mg/kg and from 2.95 to 13.18 mg/kg, respectively. Although the potency varied for both levofloxacin and ciprofloxacin among all strains of P. aeruginosa tested, there were small differences within the same strain for levofloxacin and ciprofloxacin when given in the same dosing regimen. Levofloxacin proved nearly as effective as ciprofloxacin against a systemic P. aeruginosa infection in mice.

[1]  G. Riess,et al.  Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. , 1995, The Journal of antimicrobial chemotherapy.

[2]  B. Guery,et al.  Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia , 1995, Antimicrobial agents and chemotherapy.

[3]  R. Gaynes,et al.  Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. , 1994, The Journal of infectious diseases.

[4]  B. Tümmler,et al.  Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. , 1994, The Journal of infectious diseases.

[5]  H. Richet,et al.  Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. , 1994, The Journal of infectious diseases.

[6]  S. Mitsuhashi,et al.  Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa , 1994, Antimicrobial Agents and Chemotherapy.

[7]  R. Davis,et al.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. , 1994, Drugs.

[8]  M. Berant,et al.  Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration. , 1993, The Journal of infectious diseases.

[9]  H. Grundmann,et al.  Pseudomonas aeruginosa in a neonatal intensive care unit: reservoirs and ecology of the nosocomial pathogen. , 1993, The Journal of infectious diseases.

[10]  M. Kaku,et al.  Mortality rates amongst mice with endogenous septicaemia caused by Pseudomonas aeruginosa isolates from various clinical sources. , 1993, Journal of medical microbiology.

[11]  C. Wood Quinolone resistance: a practical perspective. , 1993, Archives of internal medicine.

[12]  B. Foleno,et al.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin , 1992, Antimicrobial Agents and Chemotherapy.

[13]  S. Miyazaki,et al.  New quinolones--in vivo antibacterial activity. , 1992, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[14]  D. Collett Modelling Binary Data , 1991 .

[15]  K. Mayer,et al.  Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. , 1991, The Journal of infectious diseases.

[16]  J. Guinea,et al.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone , 1991, Antimicrobial Agents and Chemotherapy.

[17]  T. Nishino,et al.  In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin. , 1990, The Journal of antimicrobial chemotherapy.

[18]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[19]  P. Fernandes,et al.  Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. Microbiologic profile. , 1989, The Journal of antibiotics.